TAC与FAC新辅助化疗方案治疗乳腺癌的近期疗效比较

目的：比较TAC、FAC两种新辅助化疗方案治疗乳腺癌的近期疗效和不良反应。方法：将48例原发性乳腺癌患者，随机分为TAC组21例和FAC组27例，分别采用TAC（多西他赛＋吡柔比星＋环磷酰胺）方案及FAC（氟尿嘧啶at-吡柔比星＋环磷酰胺）方案进行3个周期的新辅助化疗，观察两组新辅助化疗的近期疗效及不良反应发生情况。结果：TAC组CR2例，PR15例，SD3例，PD1例，有效率为71．42％；FAC组CR1例，PR18例，SD6例，PD2例，有效率为59．26％，两组有效率比较无统计学意义（P〉0．05）。毒副反应中，FAC组白细胞减少例数明显少于TAC组（P〈0．05）；心电图改变情况、恶心呕吐、肝肾功能异常、血小板减少和脱发的例数两组比较差异无统计学意义（均P〉0．05）。结论：用TAC与FAC方案行乳腺癌新辅助化疗近期疗效比较无明显差异，但FAC方案所致的不良反应较TAC方案轻。

Comparison of Neoadjuvant Chemotherapy of Short-Term Clinical Effects between Regimens of TAC and FAC on Patients with Breast Cancer

Objective: To compare the short-term clinical effects and side effects of two neoadjuvant chemotherapy regimens of TAC and FEC.Methods: 48 cases of breast cancer patients were collected and randomly divided into TAC regimen(21 cases) and FEC regimen(27 cases).All patients were received neoadjuvant chemotherapy with TAC(docetaxel,pirarubicin,cyclophosphamide) or FAC(fluorouracil,pirarubicin,cyclophosphamide) regimen with a period of 3 weeks to observe the clinical effects and side effects of two groups.Results: Among all the 48 patients,the rate of TAC regimen was 71.42%,including 2 CR,15 PR,3 SD and 1 PD;the rate of FAC regimen was 59.26%,including 1 CR,18 PR,6 SD and 2 PD.The number of white corpuscle decrease and electrocardiogram change of FAC regimen were less than that of TAC regimen.There were no significant differences between the two regimens in the side effect(vomiting,abnormal liver function,thrombocytopenia and alopecia,etc)(P>0.05).Conclusion: The effects of the two neoadjuvant chemotherapy regimens are similar,but the side effect of FAC regimen is less serious than TAC.